Michel Zelaquett/LinkedIn
Apr 23, 2026, 07:33
Michel Zelaquett: Ultra-Minimally Invasive Treatment for Uterine Fibroids
Michel Zelaquett, Founder and Director at Centro de Mioma, shared a post on LinkedIn:
“Ultra-Minimally Invasive Treatment for Uterine Fibroids
No incisions. No scars. Minimal invasion, maximum precision.
Cutting-edge technology in service of uterine preservation and fertility — because every woman deserves access to treatments that respect her body and her future.
Proud to be part of a dedicated team pushing the boundaries of modern gynecology.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 13, 2026, 16:24Shanza Ghaffar: Recurrent Pregnancy Loss Beyond Diagnosis and Treatment
-
May 13, 2026, 16:16Alejandro González: A Historic Moment for the PCOS Community
-
May 13, 2026, 16:15Antonio La Marca: Where There Is Research, There Is Better Care
-
May 13, 2026, 16:06Mirjam Teboe: APS Diagnosis Faces False Positive Challenges in Lupus Anticoagulant Testing
-
May 13, 2026, 16:03The Link Between Lifestyle and Environmental Exposures and Endometriotic Phenotype – RBMO
-
May 13, 2026, 11:42Analysis of MED-12 Mutations in Uterine Leiomyomas of Nigerian Women – Fertility and Sterility
-
May 13, 2026, 11:33Anuja Dokras: SPIRE 2026 Brings Together the Global Fertility Community
-
May 13, 2026, 11:23Sean Lauber: Why Do Aneuploid Embryos Rarely Lead to Live Births?
-
May 13, 2026, 10:40Polyendocrine Metabolic Ovarian Syndrome, the New Name for PCOS – PCOS Awareness Association